Company profile for Sydnexis

NEW Drugs in Dev: 2
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Sydnexis Inc., is a privately held clinical stage biopharmaceutical company based in San Diego that is developing a proprietary formulation for decreasing myopic progression in children. Sydnexis recently initiated a Phase 3 study testing its patented eyedrop formulation, SYD-101.ydnexis was founded in San Diego in 2014 with the goal of developing a proprietary, stable, topical eyedrop to treat the progression of myopia in chi...
Sydnexis Inc., is a privately held clinical stage biopharmaceutical company based in San Diego that is developing a proprietary formulation for decreasing myopic progression in children. Sydnexis recently initiated a Phase 3 study testing its patented eyedrop formulation, SYD-101.ydnexis was founded in San Diego in 2014 with the goal of developing a proprietary, stable, topical eyedrop to treat the progression of myopia in children.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
445 Marine View Avenue, Suite 295 Del Mar, Ca 92014
Telephone
Telephone
858-925-6172
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251106357538/en/Sydnexis-Announces-UK-Approval-of-Ryjunea-by-Partner-Santen-to-Slow-Progression-of-Childhood-Myopia

BUSINESS WIRE
06 Nov 2025

https://www.businesswire.com/news/home/20251023759236/en/Sydnexis-Receives-Complete-Response-Letter-from-FDA-for-SYD-101-to-Slow-Pediatric-Myopia-Progression

BUSINESSWIRE
23 Oct 2025

https://www.businesswire.com/news/home/20250605515551/en/Sydnexis-Announces-European-Commission-Approval-of-SYD-101-the-First-and-Only-Pharmaceutical-Treatment-for-Slowing-the-Progression-of-Pediatric-Myopia

BUSINESSWIRE
05 Jun 2025

https://www.businesswire.com/news/home/20250501030361/en/Sydnexis-Announces-Three-Abstracts-Accepted-for-Poster-Presentations-at-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-2025-Annual-Meeting

BUSINESSWIRE
01 May 2025

https://www.businesswire.com/news/home/20250401700218/en/Sydnexis-Announces-Positive-CHMP-Opinion-in-Europe-for-SYD-101-for-Slowing-the-Progression-of-Pediatric-Myopia

BUSINESSWIRE
01 Apr 2025

https://www.businesswire.com/news/home/20250311482503/en

BUSINESSWIRE
11 Mar 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty